Skip to content

Utrogestan Versus Nifedipine as Tocolysis for Preterm Labor: a Randomised Controlled Trial

STUDY ON EFFICACY OF UTROGESTAN AS TOCOLYSIS FOR PRETERM LABOR

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01985594
Acronym
UTROGESTAN
Enrollment
32
Registered
2013-11-15
Start date
2013-11-30
Completion date
2014-10-31
Last updated
2013-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm Labor

Keywords

preterm labor

Brief summary

RESEARCH HYPOTHESIS -Incidence of preterm delivery is lower in women treated with oral micronized progesterone (Utrogestan) as acute tocolysis agent compare to Nifedipine group with fewer maternal side effect

Interventions

Oral Tablet Utrogestan 400 mg daily for 2 days

DRUGNifedipine

Tablet Nifedipine 20 mg stat then 20 mg after 30 minutes if contraction persist and another 20mg after 30 minutes if contraction still persist followed by 10 mg three times daily for 2 days

Sponsors

nor zila hassan malek
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

• Singleton pregnancy women between 22 and 34 weeks of gestation who presented with threatened preterm labor.

Exclusion criteria

* Multiple pregnancies * Women with Preterm Prelabour Rupture of Membrane * Fetal death * Women with bad obstetric history * Women with history of cervical incompetence * Contraindication to Nifedipine such as cardiovascular disease, hyperthyroidism, severe pre eclampsia or to Utrogestan * Maternal or fetal indication for immediate delivery, such as fetal distress, bleeding placenta previa, abruption placenta * Contraindication for tocolysis, for example severe pre eclampsia, intrauterine growth restriction, fetal anomaly, chorioamnionitis, significant antepartum haemorrhage * Cervical dilatation of 3cm or more * Patients with previous tocolytic treatment during this pregnancy * Women who refuse to participate in this study

Design outcomes

Primary

MeasureTime frameDescription
latency period interval between time of tocolysis and delivery24 hours up to 7 daysdelivery less than 24 hours of tocolysis,delivery less than 48 hours of tocolysis, delivery less than 7 days of tocolysis

Secondary

MeasureTime frameDescription
Pregnancy outcomes34 weeks of gestational agedelivery less than 34 weeks of gestation, delivery more than or at 34 weeks of gestation
Neonatal outcome24 hoursBirth weight (kg),cord blood acidity, need for neonatal intensive care unit admission
Maternal side effect30 minutes up to 48 hoursPalpitation,Headache, Nausea/Vomiting, Hypotension, Dyspnea, Jaundice, Pruritus

Countries

Malaysia

Contacts

Primary Contactnor zila hassan malek
nzhm_dr@yahoo.com60139823219

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026